Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-05-19
1997-12-09
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514168, 514171, 514222, 514282, A61K 3155, A61K 31595, A61K 3156, A61K 3144
Patent
active
056961146
ABSTRACT:
The invention refers to the treatment and prevention of eosinophil-mediated diseases with paf antagonists and a procedure for determining their efficacy. According to the invention for treating and prevention a disease mediated by eosinophils a combination with an effective amount of at least one paf antagonist is administered to a subject requiring said treatment of allergy and inflammation, wherein the paf antagonist is a hydrophilic or non-hydrophilic triazolothieno-diazepine or a homologue thereof, a ginkgolide, a ginkgolide mixture or a synthetic ginkgolide derivate, or an analogue of the paf or a mixture with/of these compounds.
REFERENCES:
patent: 4183912 (1980-01-01), Rosenthale
patent: 4595693 (1986-06-01), Biftu
patent: 4621083 (1986-11-01), Casals
patent: 4900729 (1990-02-01), Stransky
patent: 5147864 (1992-09-01), Wissner
patent: 5202313 (1993-04-01), Bombardelli et al.
patent: 5334592 (1994-08-01), Billah
Kornecki and Ehrlich, Science 240 (1988) 1792-1794 Neuroregulatory and Neurophathological Actions of the Ether-Phospholipid Platelet-Activating Factor.
Aronoux et al., A Rev. Respir Dis 137 (1988) 855-860 "Accumulation of Platelets and Eosinophils in Baboon Lung after PAF-Acether Challenge, Inhibition of Ketotifen".
Kroegel et al. J. Immunol. 142 (1989) 3518-3526, "Stimulation of Degranulation from human Eosinophils by Platelet-activating factor."
Snyder, Biological Membranes: Aberrations in Membrance Structure and Function (1988), 57-72, "Metabolism of Platelet Activating Factor and Related Ether Lipids: Enzymatic Pathways, Subcellular Sites, Regulation, and Membrane Processing."
Brasseur et al. Biochem. Biophys. Acta 1085 (1991) 91-105, "PAF-receptor III Conformational and Electronic Properties of PAF-like Agonists and Antagonists".
Kornecki et al. Adv. Exp. Med. Biol. 221 (1987) 477-488, "Interactions of the alkyl-ether-phospholipid, platelet activating factor (PAF) with platelets, neural cells, and the psychotropic drugs triazolobenzodiazepines".
Kornecki et al., Science 226 No. 4681 (1984) 1454-1456, "Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines."
Tiberghien C et al. J. Lipid Mediat, vol. 3, No. 3 (1991) 249-266, A competitive receptor binding assay for platelet-activating factor (PAF): Quantification of PAF in rat brain.
Gulbenkian et al. Am. Rev. Respir. Dis. vol. 142 No. 3 (1990) 680-685 "Anaphylactic challenge causes eosinophil accumulation in bronchoalveolar lavage fluid of guinea pigs. Modulation by betamethasone, phenidone, indomethacin, WEB 2086, and novel antiallergy agent, SCH 37224".
Abrahan et a. J. Appl. Physiol. vol. 66, No. 5 (1989) 2351-2357 "A possible role for PAF in allergen-induced late responses: Modificaiton by a selective antagonist."
Korth and Benveniste Eur. J. Pharmacol. 142 No. 3 (1987) 331-341 "BN 52021 platelets."
Otamiri et al. Gut, vol. 29, No. 4 (1988) 489-494 "Phospholipase A2 inhibition prevents mucosal damage associated with small intestinal ischaemia in rats."
Etienne et al. Agents and Actions vol. 17 No. 3-4 (1985) 368-370 "In Vivo inhibition of plasma protein leakage and salmonella enteritids-induced mortality in the rat by a specific Paf-acether antagonist BN 52021."
Chan-Yeung et al. J. All. Clin. Immunol. 87 (1991) 667-673, "The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction."
Yue et al. J. Pharm. and Exp. Ther. 254 (1990) 976-981, "Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits."
Bousquet et al. New Engl. J. 323 (1990) 1033-1039, "Eosinophilic inflammation in asthma."
Fradin et al. Biochim. Biophys. Acta 963 (1988) 248-257, "Inhibition of eicosanoid and PAF formation by dexamethasone in rat inflammatory polymorphonuclear neutrophils may implicate lipocortin `s`."
LandOfFree
Treatment and prevention of odema does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of odema, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of odema will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1607857